Commercial pharma partnerships and projects between pharmaceutical companies usually require the businesses involved to share highly sensitive information at an early stage. This is often before agreeing on the commercial structure of their partnership or collaborative project. As this information is so valuable, confidentiality risks must be managed carefully from the outset and contractually protected. <\/p>\n\n\n\n
Non-disclosure agreements<\/a> (NDAs) are commonly used to manage these risks in the pharmaceutical industry and wider life sciences industry. However, NDAs must be carefully reviewed to ensure they are fit for purpose and sufficiently protective to protect pharma businesses. <\/p>\n\n\n\n This article explores NDAs for risk prevention at the early stages of commercial collaboration discussions in the pharma sector. For example, for discussions around proposed research, development or other joint projects.<\/p>\n\n\n\n Many pharma partnerships can be complex and technical, and often begin with crucial initial discussions. At this stage, the disclosure of various confidential and sensitive information is often required. An NDA allows those discussions to take place while helping to limit the risk of misuse of confidential information.<\/a><\/p>\n\n\n\n Simply put, an NDA is a commercial document that sets out the rules governing how a receiving party may use confidential information. Different types of information may be shared with high sensitivity in pharma partnerships and collaborations, including: <\/p>\n\n\n\n An NDA should clearly define what is confidential and limit how the information may be used. It can be used to restrict the disclosure of confidential information and to set out rules for what must happen to the information when discussions end.<\/p>\n<\/div>\n\n\n\n A pharma partnership<\/a> NDA should clearly define what constitutes confidential information and set out the rules for handling it in practice. This can include: <\/p>\n\n\n\n Many NDAs also limit use of the information to a specific purpose, such as assessing a potential collaboration.<\/p>\n\n\n\n The key purpose is to safeguard the confidential information as much as possible and offer contractual remedies if a party breaches its obligations.<\/p>\n\n\n\n The NDA will often set out important key remedies. For instance, if a party breaches an NDA, the other party may seek damages. In some cases, they may also seek injunctive relief, such as a court order requiring the other party to stop leaking their confidential information. <\/p>\n\n\n\n Once confidential information is disclosed, the damage can be difficult to reverse. This is particularly true for business-critical information, such as: <\/p>\n\n\n\nThe Role of NDAs in Pharma Partnerships<\/h2>\n\n\n\n
\n
Key Considerations for an NDA<\/h2>\n\n\n\n
\n
\n